A Comparative Study of Adapalene Gel,0.3% Versus Tretinoin Emollient Cream, 0.05% for the Treatment of Photoaging (FOTEN)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01406080|
Recruitment Status : Completed
First Posted : July 29, 2011
Last Update Posted : April 6, 2017
The purpose of this study is to:
- Evaluate the efficacy of Adapalene gel 0.3% compared to Tretinoin Emollient cream 0.05%, reducing signs of cutaneous photoageing, measured trough photonumeric scale evaluation, investigator evaluation of global response to treatment and subject's evaluation of improvement.
- Evaluate the safety and tolerability of Adapalene Gel 0.3%, compared to Tretinoin Emollient cream 0.05% during 24 weeks of treatment.
The study has the clinical hypothesis that Adapalene Gel 0.3% is as effective as Tretinoin Emollient cream 0.05% in the treatment of cutaneous photoaging.
|Condition or disease||Intervention/treatment||Phase|
|Photoaging Photodamage||Drug: Adapalene Drug: Tretinoin||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||128 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Single-blinded, Multicenter, Randomized, Comparative Study of Efficacy and Safety of Adapalene Gel 0.3% Versus Tretinoin Emollient Cream 0.05% in the Treatment of Cutaneous Photoaging.|
|Study Start Date :||January 2013|
|Actual Primary Completion Date :||November 2015|
|Actual Study Completion Date :||November 2015|
Active Comparator: Adapalene
Differin® gel 0.3% (adapalene Gel 0,3%)
Apply approximately 1 gram of Differin 0.3% every night on the entire face, except near the eye region.
Active Comparator: Tretinoin
Tretinoin 0,05% emollient cream
Apply approximately 1 gram of Tretinoin emollient cream 0.05% every night on the entire face, except near the eye region.
Other Name: Tretinoin emollient cream 0,05%
- Assessing the extent of Cutaneous Photoaging at the end of treatment. [ Time Frame: Baseline to week 24 ]Evaluation of Cutaneous Photoaging Extension at the end of treatment: the signs of cutaneous photoaging are evaluated by means of reduction of at least one point in any one of the following parameters: periorbital wrinkles, ephelides / melanosis, forehead wrinkles, tactile roughness (texture) and actinic keratosis.
- Global Assessment of photoaging, based on the Griffiths photonumeric scale. [ Time Frame: week 24 ]The evaluator, blinded to the treatment, will assess the global degree of photoaging of the patient in all visits, based on photographic images of the Griffiths scale consisted of 5 categories (Periorbital Wrinkles, Ephelides / melanosis, Forehead Wrinkles, Tactile roughness (texture), Actinic Keratosis. These were evaluated on a scale from 0 - 4 (0 = Absent, 1 = Minimal, 2 = Mild, 3 = Moderate and 4 = Severe) with 0 being best and 4 being worst.
- Assessing the extent of Cutaneous Photoaging at each visit. [ Time Frame: week 24 ]The absolute values and changes of the Evaluation of Cutaneous Photoaging Extent in relation to baseline will be summarized by using frequency tables and at each visit and the groups will be compared.
- Evaluation of Improvement by the Investigator at Week 12 [ Time Frame: week 12 ]The evaluator, blinded to the treatment, will evaluate the improvement of the photoaging signs at week 12 using the scale 5 = important response, 4 = near complete response (≈ 90% improvement), 3 = marked response (≈ 75% improvement), 2 = moderate response (≈ 50% improvement), 1 = mild response (≈ 25% improvement), 0 = No answer, -1= Worsening.
- Evaluation of Improvement by the Investigator at Week 24 [ Time Frame: Week 24 ]The evaluator, blinded to the treatment, will evaluate the improvement of the photoaging signs at week 12 using the scale 5 = important response, 4 = near complete response (≈ 90% improvement), 3 = marked response (≈ 75% improvement), 2 = moderate response (≈ 50% improvement), 1 = mild response (≈ 25% improvement), 0 = No answer, -1= Worsening.
- Subject Assessment of improvement at week 24. [ Time Frame: week 24 ]Patients will evaluate the improvement perceived at week 24 using the following scale:0 = Improves hard to notice, 1 = A very small improvement, 2 = Small improvement, 3 = Moderate improvement, 4 = Major improvements.
- Anatomical-pathological assessment [ Time Frame: week 24 ]The difference between the treatment arms in epidermal thickness and 7.7 in the thickness of the granular layer will be detect at week 24.
- Digital morphometric assessment. [ Time Frame: week 24 ]The thickness of the stratum corneum, granular layer and the epithelium will be estimated
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01406080
|Centro de Dermatologia Dona Libania|
|Fortaleza, Ceará, Brazil, 60035-101|
|Santa Casa de Belo Horizonte|
|Belo Horizonte, Minas Gerais, Brazil, 30150-221|
|Hospital de Clínicas da Universidade Federal do Paraná|
|Curitiba, Paraná, Brazil, 80060-900|
|Universidade Federal de São Paulo - UNIFESP - UNICCO|
|São Paulo, Brazil, 04022-000|
|Study Director:||Ananda Quadros Campos||Galderma Brasil Lltda|
|Principal Investigator:||Edileia Bagatin||Universidade Federal de São Paulo|